MX2020012469A - Variante de antigeno de virus de varicela zoster y uso de la misma. - Google Patents

Variante de antigeno de virus de varicela zoster y uso de la misma.

Info

Publication number
MX2020012469A
MX2020012469A MX2020012469A MX2020012469A MX2020012469A MX 2020012469 A MX2020012469 A MX 2020012469A MX 2020012469 A MX2020012469 A MX 2020012469A MX 2020012469 A MX2020012469 A MX 2020012469A MX 2020012469 A MX2020012469 A MX 2020012469A
Authority
MX
Mexico
Prior art keywords
antigen variant
varicella zoster
zoster virus
vaccine
antigen
Prior art date
Application number
MX2020012469A
Other languages
English (en)
Inventor
Hyo Jung Nam
Ga Young Ji
Eunmi Kim
Original Assignee
Mogam Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Inst Biomedical Res filed Critical Mogam Inst Biomedical Res
Publication of MX2020012469A publication Critical patent/MX2020012469A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16771—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una variante de antígeno y un uso de la misma, siendo la variante de antígeno una proteína, entre las proteínas de superficie (gE) del virus varicela zóster, que presenta un alto nivel de expresión y alta inmunogenicidad, y por lo tanto, cuando se usa la variante de antígeno como composición de vacuna, la composición de vacuna tiene una seguridad más excelente en comparación con una vacuna de virus vivo, y la variante de antígeno presenta un nivel de expresión más alto en una célula hospedera en comparación con otros antígenos y, por lo tanto, es útil como vacuna para prevenir o tratar la varicela o el herpes zóster causado por el virus varicela zóster.
MX2020012469A 2018-05-23 2019-05-22 Variante de antigeno de virus de varicela zoster y uso de la misma. MX2020012469A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180058219 2018-05-23
PCT/KR2019/006113 WO2019225962A1 (ko) 2018-05-23 2019-05-22 바리셀라 조스터 바이러스의 항원 변이체 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2020012469A true MX2020012469A (es) 2021-02-09

Family

ID=68616069

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012469A MX2020012469A (es) 2018-05-23 2019-05-22 Variante de antigeno de virus de varicela zoster y uso de la misma.

Country Status (18)

Country Link
US (1) US11642408B2 (es)
EP (1) EP3812394A4 (es)
JP (1) JP7247226B2 (es)
CN (1) CN112189017A (es)
AU (1) AU2019272184B2 (es)
BR (1) BR112020023642A2 (es)
CA (1) CA3100462A1 (es)
CO (1) CO2020015167A2 (es)
EA (1) EA202092828A1 (es)
IL (1) IL278892A (es)
MA (1) MA51945B2 (es)
MX (1) MX2020012469A (es)
MY (1) MY195490A (es)
PE (1) PE20201415A1 (es)
PH (1) PH12020552009A1 (es)
UA (1) UA126460C2 (es)
WO (1) WO2019225962A1 (es)
ZA (1) ZA202006956B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102270048B1 (ko) 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN113683704B (zh) * 2021-07-28 2023-05-30 安徽智飞龙科马生物制药有限公司 一种水痘-带状疱疹病毒r-gE融合蛋白、重组水痘-带状疱疹疫苗及其制备方法和应用
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
CA3241245A1 (en) 2021-12-23 2023-06-29 Robert S. Janssen Immunogenicity of a cpg-adjuvanted herpes zoster vaccine
CN116284455A (zh) * 2023-04-17 2023-06-23 北京康乐卫士生物技术股份有限公司 一种带状疱疹病毒疫苗的嵌合抗原及其应用
CN117683121B (zh) * 2024-01-30 2024-04-16 北京百普赛斯生物科技股份有限公司 抗水痘-带状疱疹病毒抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180369B1 (en) * 1990-10-04 2001-01-30 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
US5824319A (en) 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
WO2006128026A2 (en) * 2005-05-26 2006-11-30 The United States Of America As Represented By Thesecretary, Dept. Of Health And Human Services National Institutes Of Health Cellular receptor for varicella-zoster virus, methods of inhibiting spread of varicella-zoster and methods of increasing stability and infectivity of the virus
WO2012106377A2 (en) * 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2012115474A2 (ko) * 2011-02-24 2012-08-30 재단법인 목암생명공학연구소 신규한 수두 대상포진 바이러스주 및 이를 이용한 수두 및 대상포진 바이러스 백신
CN102517302A (zh) * 2011-12-28 2012-06-27 中国人民解放军军事医学科学院野战输血研究所 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
CN105669838B (zh) * 2014-12-04 2020-10-16 厦门大学 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
BR112017012647A2 (pt) * 2014-12-18 2018-01-09 Glaxosmithkline Biologicals Sa composição imunogênica, método para proteção contra ou prevenção de herpes zoster (hz) e/ou neuralgia pós-herpética, e, método para proteção contra, prevenção ou redução da incidência de herpes zoster e/ou neuralgia pós-herpética.
EP4279128A3 (en) * 2015-02-25 2024-02-28 Mogam Institute for Biomedical Research Novel antibody binding to tfpi and composition comprising the same
JP6367783B2 (ja) 2015-11-26 2018-08-01 田中貴金属工業株式会社 水痘帯状疱疹ウイルス検出用免疫クロマト分析装置

Also Published As

Publication number Publication date
MA51945B2 (fr) 2023-08-31
MY195490A (en) 2023-01-26
JP7247226B2 (ja) 2023-03-28
CA3100462A1 (en) 2019-11-28
AU2019272184A1 (en) 2021-01-14
BR112020023642A2 (pt) 2021-02-17
UA126460C2 (uk) 2022-10-05
KR20210006460A (ko) 2021-01-18
PE20201415A1 (es) 2020-12-07
US11642408B2 (en) 2023-05-09
PH12020552009A1 (en) 2021-06-14
IL278892A (en) 2021-01-31
AU2019272184B2 (en) 2022-01-27
EA202092828A1 (ru) 2021-03-11
JP2021525079A (ja) 2021-09-24
MA51945A1 (fr) 2021-09-30
US20210187099A1 (en) 2021-06-24
CN112189017A (zh) 2021-01-05
WO2019225962A1 (ko) 2019-11-28
ZA202006956B (en) 2022-03-30
EP3812394A1 (en) 2021-04-28
CO2020015167A2 (es) 2020-12-21
EP3812394A4 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
PH12020552009A1 (en) Antigen variant of varicella zoster virus and use thereof
CO2018005258A2 (es) Vacuna del virus herpes simple
AU2019349036A8 (en) Immune composition, preparation method therefor, and application thereof
EA201891001A1 (ru) Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
RU2016137119A (ru) Птичьи вирусные вакцины, которые являются стабильными в жидкой среде
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
MX2021015465A (es) Vacuna para fiebre porcina africana.
BR112014011229A2 (pt) composições e métodos para o tratamento de citomegalovírus
EA201790976A1 (ru) Терапевтические вакцины против hpv16
MY159500A (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AR110632A1 (es) Vectores del adenovirus canino
EP4292659A3 (en) Antibodies that neutralize hepatitis b virus and uses thereof
EA202090049A1 (ru) Поксвирусные векторы, кодирующие антигены вич, и способы их применения
MX2021005345A (es) Composiciones y metodos.
MX2019003156A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
PE20191547A1 (es) Composicion de vacuna contra el herpes zoster
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
WO2020028719A3 (en) Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer
JP2023106591A (ja) 既存の微生物免疫を利用した癌処置
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
WO2012074881A3 (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
MX2019007924A (es) Vacunas contra la influenza.
WO2022079160A3 (en) Recombinant hvt and uses thereof
WO2023018817A8 (en) Truncated influenza neuraminidase and methods of using the same
BR112018073454A2 (pt) vacinas